QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies
Ali Mohamed Ali, Kendra K. Radtke, Anneke C. Hesseling, Jana Winckler, H. Simon Schaaf, Heather R. Draper, Belén P. Solans, Louvina van der Laan, Jennifer Hughes, Barend Fourie, James C. Nielsen, Anthony J. Garcia‐Prats, Rada Savic
Abstract
= 0.0166) compared to those when other MFX- or LFX-based regimens were used. In conclusion, we found a low risk of QTcF interval prolongation in children with RR-TB who received at least one QT-prolonging drug. Greater increases in maximum QTcF and ΔQTcF were observed when MFX and CFZ were used together. Future studies characterizing exposure-QTcF responses in children will be helpful to ensure safety with higher doses if required for effective treatment of RR-TB.
Topics & Concepts
MedicineQT intervalMoxifloxacinBedaquilineLevofloxacinRegimenPharmacologyInternal medicineTuberculosisAntibioticsMicrobiologyBiologyPathologyMycobacterium tuberculosisCardiac electrophysiology and arrhythmiasTuberculosis Research and EpidemiologyAntimicrobial Resistance in Staphylococcus